0001209191-20-024246.txt : 20200413 0001209191-20-024246.hdr.sgml : 20200413 20200413183754 ACCESSION NUMBER: 0001209191-20-024246 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200409 FILED AS OF DATE: 20200413 DATE AS OF CHANGE: 20200413 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EHRLICH JASON CENTRAL INDEX KEY: 0001754049 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38682 FILM NUMBER: 20789621 MAIL ADDRESS: STREET 1: 2631 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kodiak Sciences Inc. CENTRAL INDEX KEY: 0001468748 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270476525 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2631 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 650-281-0850 MAIL ADDRESS: STREET 1: 2631 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: Oligasis, LLC DATE OF NAME CHANGE: 20090721 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-09 0 0001468748 Kodiak Sciences Inc. KOD 0001754049 EHRLICH JASON 2631 HANOVER STREET PALO ALTO CA 94304 0 1 0 0 See Remarks Common Stock 2020-04-09 4 M 0 15000 A 37542 D Common Stock 2020-04-09 4 F 0 4058 50.67 D 33484 D Common Stock 2020-04-09 4 S 0 938 47.5394 D 32546 D Common Stock 2020-04-09 4 S 0 345 48.7046 D 32201 D Common Stock 2020-04-09 4 S 0 917 49.5478 D 31284 D Restricted Stock Units 2020-04-09 4 M 0 15000 0.00 D Common Stock 15000 15000 D Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's common stock. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting and settlement of 25% of the Reporting Person's restricted stock units granted on October 9, 2018. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e). These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. These sales were made to cover tax withholding obligations in connection with vesting and settlement of 25% of the Reporting Person's RSU granted on October 9, 2018. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $47.095 to $48.045, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $48.185 to $49.00, inclusive. The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $49.29 to $49.83, inclusive. 50% of the RSU vested 12 months after October 9, 2018 (the "Grant Date"), 25% of the RSU vested 18 months after the Grant Date and 25% of the RSU vest 24 months after the Grant Date. Chief Medical Officer and Chief Development Officer /s/ Carlton Fleming, Attorney-in-Fact for Jason Ehrlich 2020-04-13